COMMERCIALIZING WORLD-CLASS CANCER INNOVATION

Seeding and scaling Ontario’s premiere entrepreneurial ventures for patients and the economy.

ONTARIO RESEARCH Leveraging breakthrough innovation and community network COMMERCIALIZATION VENTURE Investing seed capital, creating & scaling start-ups, securing strategic partners PATIENT & ECONOMIC IMPACT Driving clinical trials, job creation, talent development, sustainable biotech in Ontario ONTARIO RESEARCH Leveraging breakthrough innovation and community network COMMERCIALIZATION VENTURE Investing seed capital, creating & scaling start-ups, securing strategic partners PATIENT & ECONOMIC IMPACT Driving clinical trials, job creation, talent development, sustainable biotech in Ontario

OUR IMPACT

Increasing the value of Ontario’s best oncology innovations and attracting investment from the private sector (current as of June 2022).

In total funding and equity investments

In additional financing attracted

Ontario start-ups created

First-in-human studies

PORTFOLIO

Our investments are at the forefront of Ontario’s biotech ecosystem.

FIND OUT MORE

FUNDS

Our investments bridge the life sciences seed funding gap.

FIND OUT MORE


KEY SUCCESSES

Our investments have resulted in significant partnerships, clinical trials, job creation and leveraged financing for the province.


RECENT NEWS

Keep up to date on our investments and business developments in recent news stories and summaries.

  • Happy Holidays from the FACIT team!

    December 5, 2022 – Your friends at FACIT wish you a healthy and relaxing holiday season. It has been a productive year and our team continues to grow the province’s biotech ecosystem through the commercialization of Ontario’s most promising cancer innovations. 

    Read More from Happy Holidays from the FACIT team!

  • FACIT’s Prospects Fund fuels women’s health and brain cancer therapies for Ontario patients

    September 28, 2022 – September 28, 2022 – FACIT congratulates Ontario-based start-ups Hyivy Health and HDAX Therapeutics as the latest recipients of capital through its Prospects Oncology Fund. Selected among a top-tier pool of applicants, these Ontario-based innovations illustrate excellent potential to benefit patients with cancer.

    Read More from FACIT’s Prospects Fund fuels women’s health and brain cancer therapies for Ontario patients

  • FACIT’s David O’Neill shares strategy for Ontario intellectual property

    June 16, 2022 – The paper “How to boost Ontario’s life sciences IP to help patients and the economy” discusses the importance of seed-stage investing and commercialization-venture partnerships to reap the benefits of taxpayers’ investment in post-secondary education and health research.

    Read More from FACIT’s David O’Neill shares strategy for Ontario intellectual property

We were established by the Ontario Institute for Cancer Research (OICR) to support commercialization, technology transfer, and development activities. OICR conducts and enables world-class cancer research, filling a critical role as a pan-provincial connector of oncology researchers, resources and cancer innovation development. Together with OICR, we drive a shared vision to attract more R&D investment in Ontario and help the best oncology innovations reach the market and save lives. 

FACIT is funded in part by the Government of Ontario through OICR